People · Operator
Named in public records as an officer, director or promoter · active 2009–2025 · Other Technology, Healthtech, Biotechnology, Business Services, Other Health Care
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Stirlingshire Investments, Inc. | — | Other Technology | Series B | $20.1M | $136.9M | 2024 |
| Seegrid Corp | — | Other Technology | Series A | $19.6M | $61.0M | 2009 |
| Genomate Health, Inc. | — | Healthtech | Series A | $10.4M | $7.7M | 2022 |
| MimiVax, LLC | — | Biotechnology | Series A | $10.0M | $361.5M | 2019 |
| Mimivax Inc. | — | Biotechnology | Series A | $5.8M | $43.3M | 2023 |
| Greenavise, Inc. | — | Business Services | Seed | $2.5M | $63.5M | 2014 |
| StimMed LLC | — | Biotechnology | Seed | $1.5M | $2.4M | — |
| Simulated Surgical Systems, LLC | — | Other Health Care | Pre-Seed | $450K | $13.9M | 2011 |
Scott Friedman at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Scott Friedman on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Jeremy Jacobs Jr. | 2 | 2 |
| Michael Ciesielski | 2 | 2 |
| Robert Fenstermaker | 2 | 2 |
| Robert Kaplan | 1 | 4 |
| Michael Sexton | 1 | 3 |
| Ashur Kalb | 1 | 3 |
| Harvey Pitt | 1 | 2 |
| Mark Kane | 1 | 2 |
| Nicole Cox | 1 | 2 |
| David Lundgren | 1 | 2 |
| David Parish | 1 | 1 |
| Paul Harder | 1 | 1 |
| Thenkuruss Kesavadas | 1 | 1 |
| Steven Woods | 1 | 1 |
| Mara London | 1 | 1 |
| Constantine Gavalas | 1 | 1 |
| Deborah Marcus | 1 | 1 |
| RICHARD SCHWAB | 1 | 1 |
| JARED SCHRIEBER | 1 | 1 |
| ISTVAN PETAK | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.